Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Sheng-Li Xue, M.D.

    Principal Investigator

    The First Affliated Hospital of Soochow University